Printed September 1, 2014 from http://www.cancer.net/about-us/cancernet-editorial-board/specialty-editors/brian-i-rini-md

Brian I. Rini, MD [1]

Cancer.Net Specialty Editor: Genitourinary Cancers

Cleveland Clinic Taussig Cancer Center, Cleveland, OH

Brian I. Rini, MD, is an Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology, Dr. Rini's work focuses on genitourinary malignancies.

Dr. Rini earned his medical degree at the Ohio State University College of Medicine in Columbus, Ohio. After completing a residency program in internal medicine at University of Chicago Hospitals in Illinois, Dr. Rini was awarded a fellowship in hematology and oncology at the University of Chicago. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to Cleveland Clinic.

At Cleveland Clinic, Dr. Rini's primary research has been in renal cell carcinoma (RCC) and prostate cancer, with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini's research has been published in peer-reviewed journals that include *Journal of the National Cancer Institute*, *Journal of Clinical Oncology*, *Cancer*, *Lancet* and *JAMA*. He is a member of the editorial boards of *Journal of Clinical Oncology* and *British Journal of Urology*.

Certified in Medical Oncology by the American Board of Internal Medicine, Dr. Rini is active in numerous professional organizations, including ASCO, American Association for Cancer Research and the Kidney Cancer Association National Medical Advisory Board.

Disclosure: In the past two years, Dr. Rini has served as a consultant/advisor to Pfizer, Bayer, Genentech, Novartis, AVEO, and GlaxoSmithKline; and has received research funding from Genentech, Bayer, Pfizer, and Wyeth.

Last Updated: May 24, 2012

Links:
[1] http://www.cancer.net/about-us/cancernet-editorial-board/specialty-editors/brian-i-rini-md